ASX Filings

Appendix 2A Update

March 25, 2021

Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD

March 15, 2021

Additional Formats

PDF Version

Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference

March 10, 2021

Additional Formats

PDF Version

Appendix 2A

March 5, 2021

Change of Director's Interest Notice - MS

March 5, 2021

Change of Director's Interest Notice - JL

March 5, 2021

Appendix 3G

March 5, 2021

Change of Director's Interest Notice - MB

March 5, 2021

Change of Director's Interest Notice - DS

March 5, 2021

Change of Director's Interest Notice - LG

March 5, 2021